Tech Company Financing Transactions
Twentyeight-Seven Therapeutics Funding Round
On 5/10/2019, Twentyeight-Seven Therapeutics raised $15 million in Series A funding from Sofinnova Ventures and Osage Partners.
Transaction Overview
Company Name
Announced On
5/10/2019
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
Sofinnova Ventures (Lead Investor) (Henrijette Richter)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
490 Arsenal Way 100B
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kazumi Shiosaki
Chief Scientific Officer
Shomir Ghosh
VP - Bus. Development
Reid Leonard
VP - R & D
Ross Stein
Browse more venture capital transactions:
Prev: 5/10/2019: Clean.io venture capital transaction
Next: 5/10/2019: Printify venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs